Experiments done in HepG2 cells demonstrate that treatment with MLRA-1812 and MLRA-1820 yielded a two-fold reduction of secreted PCSK9 levels compared to CF treatment at the same dose (Fig. 8C). This evidence concerns the gene PCSK9 and cystic fibrosis.